The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1
Kunjal Patel,Russell B Van Dyke,Murray A Mittleman,Steven D Colan,James M Oleske,George R Seage 3rd,International Maternal Pediatric Adolescent AIDS Clinical Trials 219219C Study Team,Arlene Bardeguez,Arry Dieudonne,Linda Bettica,Juliette Johnson,Stephen I Pelton,Ellen R Cooper,Lauren Kay,Ann Marie Regan,Joseph A Church,Theresa Dunaway,Audra Deveikis,Jagmohan Batra,Susan Marks,Ilaisanee Fineanganofo,Margaret A Keller,Nasser Redjal,Spring Wettgen,Sheryl Sullivan,Nancy Hutton,Beth Griffith,Mary Joyner,Carolyn Keifer,Douglas Watson,John Farley,Mary E Paul,Chivon D Jackson,Faith Minglana,Heidi Schwarzwald,Kenneth M Boyer,Jamie Martinez,James B McAuley,Maureen Haak,Michael Brady,Katalin Koranyi,Jane Hunkler,Charon Callaway,Gwendolyn B Scott,Charles D Mitchell,Claudia Florez,Joan Gamber,Diane W Wara,Ann Petru,Nicole Tilton,Mica Muscat,Teresa Courville,Karen Gold,Katherine Eng,Stephen A Spector,Rolando M Viani,Mary Caffery,Kimberly Norris,Margaret Donnelly,Kathleen McGann,Carole Mathison,John Swetnam,Tom Belhorn,Jean Eddleman,Betsy Pitkin,Vincent R Bonagura,Susan Schuval,Blanka Kaplan,Constance Colter,Elaine J Abrams,Maxine Frere,Delia Calo,William Borkowsky,Nagamah Deygoo,Maryam Minter,Seham Akleh,Diana Dobbins,Lawrence D'Angelo,Hans Spiegel,Ann J Melvin,Kathleen M Mohan,Michele Acker,Suzanne Phelps,Kenneth C Rich,Karen Hayani,Julia Camacho,A Andiman,Leslie Hurst,Janette de Jesus,Donna Schroeder,Denise Ferraro,Jane Perillo,Michele Kelly,Sohail Rana,Helga Finke,Patricia Yu,Jhoanna Roa,L A County,Andrea Kovacs,James Homans,Michael Neely,LaShonda Spencer,Mobeen H Rathore,Ayesha Mirza,Kathy Thoma,Almer Mendoza,Ana M Puga,Guillermo Talero,James Blood,Stefanie Juliano,Geoffrey A Weinberg,Barbra Murante,Susan Laverty,Francis Gigliotti,Suzanne R Lavoie,Tima Y Smith,Aditya Gaur,Katherine Knapp,Nehali Patel,Marion Donohoe,Irma L Febo,Licette Lugo,Ruth Santos,Ibet Heyer,Steven D Douglas,Richard M Rutstein,Carol A Vincent,Patricia C Coburn,Jill Foster,Janet Chen,Daniel Conway,Roberta Laguerre,Emma Stuard,Caroline Nubel,Stefan Hagmann,Murli Purswani,Mahrukh Bamji,Indu Pathak,Savita Manwani,Ekta Patel,Katherine Luzuriaga,Richard Moriarty,Barbara W Stechenberg,Donna J Fisher,Alicia M Johnston,Maripat Toye,Juan C Salazar,Kirsten Fullerton,Gail Karas,Stuart Foshee,Chitra S Mani,Denis L Murray,Christopher White,Mary Y Mancao,Benjamin Estrada,Ronald D Wilcox,Margarita Silio,Thomas Alchediak,Cheryl Borne,Shelia Bradford,David Geffen
DOI: https://doi.org/10.1097/QAD.0b013e3283578bfa
IF: 4.632
2012-10-23
AIDS
Abstract:Objective: Previous studies of cardiomyopathy among children perinatally infected with HIV were conducted before the routine use of HAART. Nucleoside analogs [nucleoside reverse transcriptase inhibitors (NRTIs)], the backbone of HAART, have been associated with mitochondrial toxicity, which can lead to cardiomyopathy. We evaluated the association of HAART and specific NRTIs associated with mitochondrial toxicity, on development of cardiomyopathy among perinatally HIV-infected children. Design: Three thousand and thirty-five perinatally HIV-infected children enrolled in a US-based multicenter prospective cohort study were followed for cardiomyopathy, defined as a clinical diagnosis or initiation of digoxin, from 1993 to 2007. Methods: Cox models were used to estimate the effects of HAART and NRTIs on cardiomyopathy, identify predictors of cardiomyopathy among HAART users, and estimate the association between development of cardiomyopathy and mortality. Results: Ninety-nine cases of cardiomyopathy were identified over follow-up (incidence rate: 5.6 cases per 1000 person-years) at a median age of 9.4 years. HAART was associated with a 50% lower incidence of cardiomyopathy compared with no HAART use (95% confidence interval: 20%, 70%). Zalcitabine (ddC) use, however, was associated with an 80% higher incidence of cardiomyopathy. Among HAART users, older age at HAART initiation, ddC use before HAART initiation, initiating a HAART regimen containing zidovudine (ZDV), and a nadir CD4 percentage less than 15% were independently associated with a higher rate of cardiomyopathy. Cardiomyopathy was associated with a six-fold higher mortality rate. Conclusion: HAART has dramatically decreased the incidence of cardiomyopathy among perinatally HIV-infected children. However, they remain at increased risk for cardiomyopathy and ongoing ZDV exposure may increase this risk.